CLAIMS

What is claimed is:

1. A compound selected from the group consisting of:
2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate;
2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate;
2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide monofumarate;
2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide hemifumarate; and
2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide hemifumarate dihydrate.

2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition prepared by formulating a compound according to claim 1 with one or more pharmaceutically acceptable carriers.

4. A process for preparing a pharmaceutical composition comprising formulating a compound according to claim 1 with one or more pharmaceutically acceptable diluents.

5. The compound 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate according to claim 1.

6. The compound according to claim 5 in crystalline form.

7. A pharmaceutical composition comprising the compound according to claim 5 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition prepared by formulating the compound according to claim 5 with one or more pharmaceutically acceptable carriers.

9. A process for preparing a pharmaceutical composition comprising formulating the compound according to claim 5 with one or more pharmaceutically acceptable diluents.

10. The compound 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate according to claim 1, in crystalline form.

11. The compound 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide monofumarate according to claim 1, in crystalline form.

12. The compound 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide hemifumarate according to claim 1, in crystalline form.

13. The compound 2-(cyclohexylmethyl)-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide hemifumarate dihydrate according to claim 1, in crystalline form.

14. A process for the manufacture of the 2-(cyclohexylmethyl)-*N*-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate comprising the steps of contacting, under elevated temperature or at ambient temperature, 2-(cyclohexylmethyl)-*N*-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide dissolved in a suitable solvent or in a mixture of solvents, with fumaric acid, optionally dissolved in a solvent or in a mixture of solvents; and isolating the precipitated solid.

15. Use of the compound according to claim 1 for the treatment of a disease or disorder selected from the group consisting of obesity, diabetes, vigilance disorders, sleep disorders, narcolepsy, Alzheimer's disease, dementia, Parkinson's disease, attention-deficit hyperactivity disorder, memory disorders, learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, sexual dysfunction, dizziness, and travel sickness.

16. A method for treating a disease or disorder selected from the group consisting of obesity, diabetes, vigilance disorders, sleep disorders, narcolepsy, Alzheimer's disease, dementia, Parkinson's disease, attention-deficit hyperactivity disorder, memory disorders, learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, sexual dysfunction, dizziness, and travel sickness; said method comprising

administering to a patient in need of said treatment a pharmaceutically effective amount of the compound according to claim 1.

CLAIMS

What is claimed is:

1. A compound 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate in the crystalline Form I.

2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition prepared by formulating a compound according to claim 1 with one or more pharmaceutically acceptable carriers.

4. A process for preparing a pharmaceutical composition comprising formulating a compound according to claim 1 with one or more pharmaceutically acceptable diluents.

5. A process for the manufacture of the 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide difumarate monohydrate according to claim 1 comprising the steps of contacting, under elevated temperature or at ambient temperature, 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide dissolved in a suitable solvent or in a mixture of solvents, with fumaric acid, optionally dissolved in a solvent or in a mixture of solvents; and isolating the precipitated solid.

6. The pharmaceutical composition according to claim 3, which is in a solid dosage form.